Full Text View
Tabular View
Study Results
Related Studies
Study of Transitioning From Alendronate to Denosumab
This study has been completed.
Study NCT00377819   Information provided by Amgen

First Received on September 14, 2006.   Last Updated on June 30, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Postmenopausal Osteoporosis
Additional conditions recognized in this trial
Osteoporosis
Osteoporosis, Postmenopausal
More general conditions related to this trial
Bone Diseases
Bone Diseases, Metabolic
Musculoskeletal Diseases
Interventions listed in this trial
alendronate
Denosumab (AMG 162)
More general drug interventions related to this trial
Bone Density Conservation Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Amgen


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services